Sabiad

Sabiad BV is a private, pre-revenue biotech company founded in 2022 (operationally active since 2019) and based in Amsterdam, Netherlands. It is commercializing over two decades of academic research into staphylococcal proteins, centered on a patented antibody (1D9) for theranostic applications. The company's core technology, StaphMark, is designed to precisely image and treat bacterial infections in real time, targeting a critical unmet need in orthopedic surgery and infectious disease. Sabiad's approach has the potential to transform infection management by enabling localized, targeted interventions that could lower healthcare costs and combat antibiotic resistance.

Patented StaphMark theranostic platform based on the 1D9 human monoclonal antibody that targets Staphylococcus aureus. It enables real-time imaging/detection and targeted delivery of therapeutic payloads to infection sites, with claimed capabilities in biofilm disruption.

The field of infectious disease theranostics is nascent, giving Sabiad a potential first-mover advantage. However, it competes indirectly with advanced molecular diagnostics companies and developers of targeted antimicrobials or anti-biofilm therapies. Success will depend on demonstrating superior clinical utility over these fragmented standard-of-care approaches.